Results 1 to 10 of about 35,513 (255)

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives. [PDF]

Eur J Haematol
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gaidano G, Danesi R.
europepmc   +2 more sources

Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. [PDF]

Front Oncol
Oura M, Toho M, Ikeda D, Fukuda N, Torres AS, Fujii F, Sakuma H, Uehara A, Tabata R, Narita K, Takeuchi M, Matsue K.   +11 more
europepmc   +1 more source

Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions. [PDF]

Leukemia
Tavarozzi R, Maher N, Catania G, Zacchi G, D'Andrea F, Sofia A, Zanni M, Ladetto M.   +7 more
europepmc   +1 more source

Acalabrutinib treatment in relapsed/refractory primary cutaneous diffuse large B cell lymphoma, leg type. Case report. [PDF]

Front Oncol
Martinez-Gamboa DA, Beas FF, Moreno-Cortes E, Swanson LA, Mangold AR, Vargas F, Castro JE.   +6 more
europepmc   +1 more source

Bruton Tyrosine Kinase Inhibition in Combination With Bispecific Antibodies for Richter's Syndrome: A Report of Two Cases and Mini Review. [PDF]

Cureus
Hane BC, Hoffmann M, Zhang D, Chopra S, Bennett J.   +4 more
europepmc   +1 more source

Latest advances in frontline CLL treatment from the 2025 ASH congress. [PDF]

Ann Hematol
Visentin A.
europepmc   +1 more source

Cost Effectiveness of First-Line Therapies for Treatment-Naïve Chronic Lymphocytic Leukaemia in South Africa. [PDF]

Clin Drug Investig
Woudberg R, Sinanovic E.
europepmc   +1 more source

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab. [PDF]

Br J Haematol
Allsup DJ, Cairns DA, Samy EF, Duley L, Bloor A, Varghese A, Meads D, Dawkins B, Girvan S, Howard DR, Hockaday A, Brown JM, Jackson S, Greatorex N, Templeton P, Tupper M, Phillips D, Yaqub S, Mortimer D, Stones D, Patten PEM, Rawstron A, Hillmen P, Munir T.   +23 more
europepmc   +1 more source

CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer. [PDF]

Cell Death Dis
Sun S, Huang L, Ma Y, Wei Z, Zhu M, Chen M, Ying F, Zhou X, Yang P, Wen Y, Yang Q, Cai L, Zhang Y, Cai J.   +13 more
europepmc   +1 more source

Letter to the Editor: Combination of FTO and BTK inhibitors synergistically suppresses the malignancy of breast cancer cells. [PDF]

Int J Biol Sci
Liu M, Zhao Z.
europepmc   +1 more source